A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 8, 2011, Pages 1015-1021

  Wakuda, Hirokazu ^a,b   Nejime, Namie ^a   Tada, Yukari ^a   Kagota, Satomi ^a   Fahmi, Odette A ^d   Umegaki, Keizo ^c   Yamada, Shizuo ^b   Shinozuka, Kazumasa ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Caco 2 cells; Confocal laser scanning microscopy; Digoxin; P glycoprotein; St John's wort

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; RHODAMINE 123;

ANALYTICAL EQUIPMENT; APICAL MEMBRANE; ARTICLE; CELL STRAIN CACO 2; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE MICROPLATE; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MOLECULAR IMAGING; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TRANSPORT; SCREENING; SENSITIVITY AND SPECIFICITY; WHOLE CELL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; DRUG INTERACTIONS; FLUORESCENT DYES; HUMANS; HYPERICUM; MICROSCOPY, CONFOCAL; P-GLYCOPROTEIN; PLANT EXTRACTS; RHODAMINE 123;

EID: 79959909035     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01294.x     Document Type: Article

References (56)

1. Sugawara I et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48: 1926-1929.
2. Cordon-Cardo C et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86: 695-698. (Pubitemid 19037807)
3. Ling V et al. Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983; 68: 869-874. (Pubitemid 14231377)
4. Pederson KE et al. Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983; 24: 41-47. (Pubitemid 13181784)
5. Hedman A et al. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 1990; 47: 20-26. (Pubitemid 20041205)
6. Koren G et al. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol 1998; 40: 45-46. (Pubitemid 28087270)
7. Fromm MF et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 472-474.
8. Partanen J et al. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996; 79: 274-276. (Pubitemid 26374172)
9. Jalava KM et al. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-613.
10. Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanism. Ann Pharmacother 1998; 31: 438-440.
11. Greiner B et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
12. Roby CA et al. St. John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67: 451-457. (Pubitemid 30327483)
13. Whitten DL et al. The effect of St. John's wort extracts on CYP3A4: a systematic review of prospective clinical trial. Br J Clin Pharmacol 2006; 62: 512-526. (Pubitemid 44571572)
14. Perloff MD et al. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601-1608. (Pubitemid 34038092)
15. Shord SS et al. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009; 8: 208-227.
16. Di YM et al. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008; 14: 1723-1742.
17. Ruschitzka F et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548-549. (Pubitemid 30088678)
18. Breidenbach T et al. Profound drop of cyclosporine A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 2000; 69: 2229-2230. (Pubitemid 30395071)
19. Mal I et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000; 38: 500-502.
20. Gurley BJ et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772-779.
21. Bacic-Vrca V et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010; 32: 815-821.
22. Girre V et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol 2011; 78: 220-226.
23. Annaert PP, Brouwer KL. Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2005; 33: 388-394. (Pubitemid 40279939)
24. Wang Y et al. A kinetic study of Rhodamine 123 pumping by P-glycoprotein. Biochem Biophys Acta 2006; 1758: 1671-1676. (Pubitemid 44466701)
25. Kageyama M et al. In vivo effects of cyclosporine A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rat. Biol Pharm Bull 2005; 28: 316-322. (Pubitemid 40880016)
26. Parasrampuria R, Mehvar R. Effects of P-glycoprotein and Mrp2 inhibitors on the hepatobiliary disposition of Rhodamine 123 and its glucuronidated metabolite in isolated perfused rat livers. J Pharm Sci 2010; 99: 455-466.
27. Perloff MD et al. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003; 20: 1177-1183. (Pubitemid 36951842)
28. Van der Sandt IC et al. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 2000; 11: 207-214.
29. Kohji T et al. Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 2002; 292: 190-194.
30. Lowry OH et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
31. Okura T et al. Effects of several dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010; 33: 255-259.
32. Aller SG et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-1722.
33. Varma MV et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359. (Pubitemid 36945333)
34. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40.
35. Seithel A et al. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 2006; 28: 291-299. (Pubitemid 44218740)
36. Krüger P et al. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sci 2009; 36: 275-284.
37. Kis O et al. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther 2010; 334: 1009-1022.
38. Matsumoto S et al. Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: interaction with dipeptide transport systems in apical and basolateral membranes. J Pharmacol Exp Ther 1994; 270: 498-504. (Pubitemid 24271357)
39. Dantzig AH et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 1994; 264: 430-433. (Pubitemid 24178907)
40. Zrieki A et al. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol 2010; 636: 189-197.
41. Hunter J et al. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993; 268: 14991-14997. (Pubitemid 23206648)
42. Artusson P et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43.
43. Thiebaut F et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738.
44. Cordon-Cardo C et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287. (Pubitemid 20266126)
45. Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466-475. (Pubitemid 351537792)
46. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113: 315-324.
47. Korjamo T et al. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm Res 2006; 23: 1991-2001.
48. Schrickx J, Fink-Gremmeis J. P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. J Vet Pharmacol Ther 2007; 30: 25-31. (Pubitemid 46066506)
49. Bailey DG et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
50. Nowack R et al. Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients. Clin Pharmacol Ther 2009; 85: 439-443.
51. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131-2145.
52. Becquemont L et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311-316. (Pubitemid 33022471)
53. Parker RB et al. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003; 23: 979-987. (Pubitemid 36903998)
54. Shirasaka Y et al. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 2010; 332: 181-189.
55. Hou XL et al. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm 2008; 358: 224-229.
56. Ampasavate C et al. Effects of Curcuma spp. on P-glycoprotein function. Phytomedicine 2010; 17: 506-512.